Skip to main content

Table 1 Twenty-eight-day mortality for all patients enrolled in ADDRESS and for sequence subgroups

From: Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsis

 

Drotrecogin alfa (activated)

Placebo

Relative risk

95% CI

Breslow-Day P value

 

Number

Died (percentage)

Number

Died (percentage)

   

All randomly assigned patients

1,316

243 (18.47)

1,297

221 (17.04)

1.08

0.92, 1.28

 

Patient classification

      

0.04

   First patient only

260

58 (22.31)

249

36 (14.46)

1.54

1.06, 2.25

 

   Excluding first patient

1,056

185 (17.52)

1,048

185 (17.65)

0.99

0.82, 1.19

 
  1. ADDRESS, ADministration of DRotrecogin alfa (activated) in Early Stage Severe Sepsis; CI, confidence interval.
Back to article page

Critical Care

ISSN: 1364-8535